21th PAGE Meeting

Venice - Italy
5-8 June, 2012

View abstracts

Home / 2012 – Venice – Italy / Abstracts

← Back to filters

Abstracts (20)

I-34Thu Thuy Nguyen

Modelling the impact of fecal ciprofloxacin concentrations on fecal counts of resistant Enterobacteriaceae in piglets treated with ciprofloxacin: towards new means to control the spread of resistance?

Wednesday 10:15-11:45

I-37Elisabet Nielsen

Target Attainment Analysis to Evaluate Dosing Regimens of an Oral β-Lactam Antibioic

Wednesday 10:15-11:45

I-57Dinko Rekic

External validation of the bilirubin-atazanavir nomogram for assessment of atazanavir plasma exposure in HIV-1 infected patients

Wednesday 10:15-11:45

II-08

Simultaneous population pharmacokinetic modelling of atazanavir and ritonavir in HIV-infected adults and assessment of different dose reduction strategies

Wednesday 15:10-16:40

II-13Satoshi Shoji

Population Pharmacokinetics/Pharmacodynamics of Ampicillin/Sulbactam in Patients with Moderate or Severe Community-Acquired Pneumonia

Wednesday 15:10-16:40

II-34Nadia Terranova

Modelling of protozoa dynamics and drug effects in a murine model of malaria infection

Wednesday 15:10-16:40

II-52Max von Kleist

PK-PD Modelling of the Reverse Transcriptase Inhibitor Tenofovir and Quantification of its Prophylactic Efficacy against HIV-1 Infection

Wednesday 15:10-16:40

II-64Chao Zhang

Model-based evaluation of the pharmacokinetic differences between adults and children administered lopinavir and ritonavir in combination with rifampicin

Wednesday 15:10-16:40

III-02

Pragmatic Approach for Interpreting Antiretroviral Drug Concentrations Based on a Systematic Review of Population Pharmacokinetic Studies

Thursday 10:05-11:35

III-08Eduardo Asín-Prieto

Population pharmacokinetics of piperacillin in critically ill patients undergoing continuous renal replacement therapies

Thursday 10:05-11:35

III-18Kirsten Bergmann

Comparing a mechanistic with an empirical approach to assess resistance development of antibacterials in vitro.

Thursday 10:05-11:35

III-19Julie Bertrand

Population Pharmacokinetic-Pharmacogenetic study of Efavirenz in combination with anti-TB treatment in HIV-Infected Cambodian Patients

Thursday 10:05-11:35

III-29Margreke Brill

Population pharmacokinetic model for cefazolin in serum and subcutaneous adipose tissue in morbidly obese and normal weight patients

Thursday 10:05-11:35

III-37Ayyappa Chaturvedula

Development of population pharmacokinetic model for Tenofovir using sparsely sampled subject data

Thursday 10:05-11:35

III-53Paolo Denti

Population pharmacokinetics of ritonavir-boosted darunavir together with efavirenz in healthy volunteers

Thursday 10:05-11:35

IV-33Stefanie Hennig

Pharmacokinetics of tobramycin do not differ in patients with and without cystic fibrosis

Thursday 15:00-16:30

IV-35Richard Höglund

A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated P.falciparum malaria

Thursday 15:00-16:30

IV-48

Population pharmacokinetic analysis of colistin in burn patients

Thursday 15:00-16:30

IV-57David Khan

In silico predictions of in vitro growth competition experiments between wild type and resistant mutants of E. coli MG1655 exposed to ciprofloxacin

Thursday 15:00-16:30

IV-58Frank Kloprogge

Population pharmacokinetics of lumefantrine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Uganda

Thursday 15:00-16:30